Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-04-10
2007-04-10
Chen, Shin-Lin (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S320100, C435S455000, C435S463000, C536S023100, C536S023500
Reexamination Certificate
active
10762888
ABSTRACT:
Human pre-formed xenoantibodies play an important role in the hyperacute rejection response in human xenotransplantation. Disclosed are materials and methods for removing or neutralizing such antibodies. Also disclosed are materials and methods for reducing or eliminating the epitopes in the donor organs that are recognized by such antibodies. Such epitopes are formed as the result of activity by the enzyme α-1,3 galactosyltransferase. The porcine gene encoding α-1,3 galactosyltransferase is disclosed, as are materials and methods for inactivating (“knocking out”) the α-1,3 galactosyltransferase gene in mammalian cells and embryos. Included are nucleic acid constructs useful for inactivating the α-1,3 galactosyltransferase gene in a target cell. Also disclosed is a novel leukemia inhibitory factor (T-LIF) that is useful for maintenance of embryonic stem cells and primordial germ cells in culture.
REFERENCES:
patent: PL 7854 (1994-10-01), None
patent: 2011784 (1990-03-01), None
patent: 2157659 (1994-09-01), None
patent: 235805 (1987-09-01), None
patent: WO 88/07548 (1988-10-01), None
patent: WO 90/03432 (1990-04-01), None
patent: WO 90/08188 (1990-07-01), None
patent: WO 91/13985 (1991-09-01), None
patent: WO 91/19796 (1991-12-01), None
patent: WO 92/07581 (1992-05-01), None
patent: WO 93/16729 (1993-09-01), None
patent: WO 94/02616 (1994-02-01), None
patent: WO 94/21799 (1994-09-01), None
Verma et al., Sep. 1997, Nature, vol. 389, pp. 239-242.
Eck et al., 1996, Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, p. 77-101.
Gorecki, 2001, Expert Opin. Emerging Drugs, 6(2): 187-198.
GenBank Nucleotide Sequence Access No. NCBI: J04989, deposited Apr. 27, 1993.
GenBank Nucleotide Sequence Access No. NCBI: X12810, deposited Mar. 31, 1995.
GenBank Nucleotide Sequence Access No. NCBI: X13967, deposited Sep. 9, 2004.
Abstracts from the 2nd International Congress on Xenotransplantation, Cambridge, England, Sep. 26-29, 1993.
Abstracts from 11th Meeting of Transplant Society of Australia and New Zealand, Australia, May 5-7, 1993.
Letter to Examiner disclosing grounds for an opposition filed by the Austin Research Institute in corresponding Australian patent application No. 711,144 (2 pages).
Fournier et al., “A Human Naturally Occurring Antibody, Anti-Gal, Recognises Epitopes in Pig Kidney, Heart and Liver and is Cytotoxic to Endothelial Cells in the Presence of Rabbit Complement,” Abstract, #113, p. 142, Second International Congress on Xenotransplantation held in Cambridge, England Sep. 26-29, 1993.
Dabkowski et al., “Isolation of a cDNA Clone Encoding the Pig α1,3 Galactosyltransferase,” Transplantation Proceedings 26(3):1335, 1994.
Cooper et al., “Genetically engineered pigs,” The Lancet 342:682-683, 1993.
Hogan et al., “Getting nearer the mark,” Nature 336:304-305, 1988.
Mansour et al., “Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes,” Nature 336:348-352, 1988.
O'Gorman et al., “Recombinase-Mediated Gene Activation and Site-Specific Integration in Mammalian Cells,” Science 251:1351-1355, 1991.
Capecchi, “Tapping the cellular telephone,” Nature 344:10, 1990.
Alberts et al., (eds.)Molecular Biology of the Cell, Garland Publishing, Inc.: New York and London, 1989, pp. 194, 195, 894-896, 900, 901.
Sandrin et al., “Studies on Human Naturally Occurring Antibodies to Pig Xenografts,” Transplantation Proceedings, 25(5):2917-2918, 1993.
Vaughan et al., “Biochemical Analysis of Pig Xenoantigens Detected by Human Antibodies,” Transplantation Proceedings 25(5):2919-2920, 1993.
Mortensen, “Double Knockouts: Production of Mutant Cell lines in Cardiovascular Research,” Hypertension 22:646-651, 1993.
Robertson, “Embryo-derived stem cell lines,” InTeratocarcinomas and embryonic stem cells: a practical approach, E.J. Robertson (ed.), IRL Press: Oxford, England, 1987, Chapter 4.
Zijlstra et al., “Germ-line transmission of a disrupted B2-microglobulin gene produced by homologous recombination in embryonic stem cells,” Nature 342:435-438, 1989.
Merlino, “Transgenic animals in biomedical research,” FASEB J. 5:2996-3001, 1991.
Broach et al., “Replication and Recombination Functions Associated with the Yeast Plasmid, 2μ Circle,” Cell 21:501-508, 1980.
Thall et al., “Oocyte Galα1,3Gal Epitopes Implicated in Sperm Adhesion to the Zona Pellucida Glycoprotein ZP3 Are Not Required for Fertilization in the Mouse,” The Journal of Biological Chemistry 270(37):21437-21440, 1995.
Tearle et al., “The α-1,3-Galactosyltransferase Knockout Mouse,” Transplantation 61:13-19, 1996.
McKenzie et al., “Human Lymphocytotoxic and Haemagglutinating Activity Against Sheep and Pig Cells,” The Lancet, Aug. 17, 1968, 386-387.
Galili et al., “A Unique Natural Human IgG Antibody with Anti-α-Galactosyl Specificity,” J. Exp. Med. 160:1519-1531, 1984.
Cosgrove et al., “Mice Lacking MHC Class II Molecules,” Cell 66:1051-1066, 1991.
Sandrin et al.,Proc. Natl. Acad. Sci. USA, 90:11391-11395 (1993).
Liu et al.,Int. J. Dev. Biol., 39:639-644 (1995).
Matsui et al.,Cell, 70:841-847 (1992).
Sandrin et al.,Immunological Reviews, 141:169-190 (1994).
Gustafsson et al.,Immunological Reviews, 141:59-70 (1994).
Galili,Immunology Today, 14:480-482 (1993).
Larsen et al,Proc. Natl. Acad. Sci. USA, 86:8227-8231 (1989).
Fletcher et al.,J. of Exp. Medicine, 174:837-845 (1991).
Samal et al.,Biochimica et Biophysica Acta, 1260:27-34 (1995).
Willson et al.,European J. of Biochem., 204:21-30 (1992).
Gough et al.Proc. Natl. Acad. Sci., 85:2623-2627 (1988).
Gearing et al.,Nucleic Acids Res., 16:9857 (1988).
Moreau et al.,Nature, 336:690-692 (1988).
Gearing et al.,Bio/Technology, 7:1157-1161 (1989).
Yamamori et al.,Science, 246:1412-1416 (1989).
Lowe et al.,DNA, 8:351-359 (1989).
Stahl et al.,J. Biol. Chem., 265:8833-8841 (1990).
Vaughan et al.,Transplantation, 58:879-882 (1994).
Latinne et al.,Immunological Reviews, 141:95-125 (1994).
Soares et al.,Transplantation, 57:1003-1009 (1994).
Soares et al.,Transplantation, 56:1427-1433 (1993).
Gambiez et al.,Transplantation, 54:577-583 (1992).
Oriol et al.,Transplant Internationa, 7:405-413 (1994).
Hale et al.,Blood, 62:873-882 (1983).
Dabkowski et al.,Transplant. Proc., 25:2921 (1993).
Paulson et al.,J. Biol. Chem., 264:17615-17618 (1989).
Joziasse et al.,J. Biol. Chem., 267:5534-5541 (1992).
Thomas et al.,Cell, 51:503-512 (1987).
Capecchi,Trends in Genetics, 5:70-76 (1989).
Jung et al.,Science, 259:984-987 (1993).
Joziasse et al.,J. Biol. Chem., 264:14290-14297 (1989).
Brinster et al.,Proc. Nat. Acad. Sci. USA, 86:7087-7091 (1989).
Rathjen et al.,Cell, 62:1105-1114 (1990).
Galili,The Lancet, pp. 358-360, Aug. 12, 1989.
Thall et al.,Autoimmunity, 10:81-87 (1991).
Good et al.,Transplant. Proc., 24:559-62 (1992).
Galili,Springer Sem. Immunopathol., 15:155-71 (1993).
Galili,Xeno, 2:84-87 (1994).
Resnick et al.,Nature, 359:550-551 (1992).
Capecchi, M.R., (ed.),Molecular Genetics of Early Drosophilia and Mouse Developmentpp. 39-44 (Cold Springs Harbor Lab. Press, 1989).
Jaenisch, R.,Science, 240:1468-1474 (1988).
Laus, et al.,Int. Archs Allergy Appl. Immun., 85:201-207 (1988).
Hendricks, S.P., et al.,J. Bio. Chem., 265:17621-17626 (1990).
Platt, J.L., et al.,Transplantation, 50:817-822 (1990).
Galili, U., et al.,J. Bio. Chem., 263:17755-17762 (1988).
Smith, D.F., et al.,J. Fed. Am. Soc. Exp. Biol., 4:A1979 (1990).
Hindsgaul, D., et al.,J. Bio. Chem., 266:17858-17862 (1991).
Cooper, D.K.C., et al.,Transplantation Proceedings, 24:566-571 (1992).
Cooper, D.K.C., et al.,Xeno-transplantation, pp. 47-99, 170-178, 312-321, 429-438, 500-510, (Springer-Verlag Berlin Heidelberg, 1991).
Platt, J.L., et al.,Immunology, 3:735-739 (1991).
Miyagawa, S., et al.,Transplantation Pro
Crawford Robert J.
d′Apice Anthony J. F.
Pearse Martin J.
Rathjen Peter D.
Robins Allan J.
BresaGen Limited
Chen Shin-Lin
Fish & Richardson P.C.
St. Vincent's Hospital
LandOfFree
Materials and methods for management of hyperacute rejection... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Materials and methods for management of hyperacute rejection..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods for management of hyperacute rejection... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3770232